France-based hospital CHU Bordeaux has gone live on SOPHiA DDM Platform, a cloud-native software solution by Sophia Genetics.

The hospital will utilise the platform to advance its research on cancers with Homologous Recombination Repair (HRR) mutations.

HRR is a DNA repair pathway that affects certain types of cancers, and deficiencies in this pathway can lead to gene mutations and genomic instability.

The SOPHiA DDM Platform leverages artificial intelligence (AI) and machine learning to analyse complex next-generation sequencing (NGS) data associated with HRR mutations.

This platform will help CHU Bordeaux streamline its bioinformatics workflow for analysing NGS data and establish an in-house database from the genomics profiles it studies.

SOPHiA GENETICS managing director Kevin Puylaert said: “Our goal at SOPHiA GENETICS is to help facilitate research and insights for serious conditions such as cancer to enable the widespread adoption of precision medicine as the gold standard of treatment.

“In line with our goal, customers like CHU Bordeaux that are dedicated to research, and medical innovation are embracing the foundations for precision medicine by adopting the SOPHiA DDM Platform.

“This will enable the hospital to advance its research on HRR-mutated tumors and be better informed to make data-driven decisions.”

SOPHiA GENETICS aims to promote data-driven medicine as a standard of care through its innovative platform and solutions.

Last week, SOPHiA GENETICS announced the expansion of its alliance with French cancer centre Gustave Roussy.